Key Highlights
- Adam Laponis joins Twist Bioscience as the Chief Financial Officer, bringing extensive experience from small cap and Fortune 50 companies.
- Laponis’s background includes roles in large pharma, automobile manufacturers, and start-up environments, positioning him well for Twist’s growth and profitability aims.
- Twist Bioscience continues to lead in synthetic biology and genomics, focusing on innovative DNA synthesis and applications in healthcare, agriculture, and more.
Source: Business Wire
Notable Quotes
- “Adam’s deep financial acumen and strategic planning expertise across diverse businesses make him an ideal fit for our next phase of growth.” – Emily M. Leproust, Ph.D., CEO and Co-founder at Twist Bioscience
- “I’m particularly excited to join Twist at this pivotal time as the company is moving toward cash flow breakeven.” – Adam Laponis, Chief Financial Officer at Twist Bioscience
SoH's Take
The appointment of Adam Laponis as CFO of Twist Bioscience signifies a strategic move for the company, focusing on enhancing financial leadership to support its innovative synthetic DNA technology. Laponis’s diverse experience in finance and operations across various sectors aligns with Twist’s goals of scaling business, driving profitability, and expanding its market presence. This appointment could be a catalyst in strengthening Twist’s financial framework, crucial for its ambitious projects in health, food security, and sustainability. Given Laponis’s track record of facilitating growth and his alignment with mission-driven companies, his leadership is poised to steer Twist towards its financial and operational objectives effectively.
